Anti-HL-60 Antigen / Human Leukemia Antigen (IPO-M6)

This antibody reacts with human leukemia cell line HL-60 and immunoprecipitates two proteins with MW of 48 kDa and 52 kDa. It does not stain B-cell lines Daudi, PHS, Namalwa, RPMI-1788 and T-cell lines CCRF-HSB2, Jurkat and Molt-4. This antibody stains monocytes and up to 10% of lymphocytes from peripheral blood of healthy donors. Blast cells of patients with AMMonL (M5 following FAB classification), AMMonL (M4) and hairy cells leukemia are positive. Its antigen is particularly expressed on blood cells from patients with infectious mononucleosis and CLL. Histiocytes and macrophages are also positive. Malignant cells from patients with AML (M1 and M2), T-ALL, B-ALL are not stained. HL-60 cells are used as an in vitro model of acute promyelocytic leukaemia and for differentiation and apoptosis studies. The HL60 cell line was established in 1977 from a patient with acute myeloid leukaemia. The cells largely resemble promyelocytes but can be induced to differentiate terminally in vitro. Some reagents cause HL60 cells to differentiate to granulocyte-like cells, others to monocyte/macrophage-like cells. The HL60 cell genome contains an amplified c-myc proto-oncogene; c-myc mRNA levels are correspondingly high in undifferentiated cells but decline rapidly following induction of differentiation.Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.